Verastem Inc (FRA:2VSA)
€ 3.7 -0.34 (-8.42%) Market Cap: 158.44 Mil Enterprise Value: 109.90 Mil PE Ratio: 0 PB Ratio: 13.49 GF Score: 32/100

Verastem, Inc. - Special Call Transcript

Sep 16, 2020 / 12:00PM GMT
Release Date Price: €13.8 (-4.33%)
Operator

Good morning, and welcome to the Verastem Oncology Investor Conference Call on Wednesday, September 16, 2020. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.

At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.

John Doyle
Verastem, Inc. - VP of IR & Finance

Welcome, everyone, and thank you for joining us this morning. With me today to discuss the updated clinical data from the ongoing Phase I/II FRAME study investigated in the combination of VS-6766 and defactinib in low-grade serous ovarian cancer are: Brian Stuglik, Chief Executive Officer; Dan Paterson, President and Chief Operating Officer; Rob Gagnon, Chief Financial Officer; and Dr. Rachel Grisham, Medical Oncologist, Memorial Sloan Kettering Cancer Center and the Co-Principal Investigator of the upcoming registration-directed trial in low-grade serous ovarian cancer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot